论文部分内容阅读
目的:了解某些抗癫痫“纯中药”制剂中是否含有抗癫痫西药成分,为临床合理用药提供依据。方法:对服用“纯中药”制剂的30例癫痫患者,用荧光偏振免疫法(FPIA)筛检其是否含有丙戊酸(VPA)、卡马西平(CBZ)、苯巴比妥(PB)、苯妥英钠(DPA)等4种常用抗癫痫西药。结果:30例患者中,检测出上述1～4种常用抗癫痫西药的28例,占93.3%。其中VPA 16例,平均浓度(12.02±14.97)μg·ml~(-1);CBZ 20例,平均浓度(2.43±2.54)μg·ml~(-1);PB 23例,平均浓度(14.57±16.63)μg·ml~(-1);DPA 22例,平均浓度(7.31±13.43)μg·ml~(-1)。结论:在所谓的抗癫痫“纯中药”制剂中暗加西药较普遍,严重侵犯了患者知情权,妨碍了抗癫痫的正规治疗,有损患者健康。
Objective: To understand whether some anti-epilepsy “pure Chinese medicine” preparations contain anti-epileptic western medicine ingredients, so as to provide basis for clinical rational drug use. Methods: Thirty patients with epilepsy who received “pure Chinese medicine ” preparations were screened by fluorescence polarization immunoassay (FPIA) for VPA, CBZ and PBT ), Phenytoin sodium (DPA) and other four commonly used anti-epileptic western medicine. Results: Of the 30 patients, 28 cases of the above-mentioned 1 ~ 4 commonly used anti-epileptic western medicine were detected, accounting for 93.3%. Including 12 cases of VPA (average 12.02 ± 14.97 μg · ml -1), 20 cases of CBZ (average 2.43 ± 2.54 μg · ml -1), 23 cases of PB (average 14.57 ± 16.63) μg · ml ~ (-1); 22 cases of DPA with the average concentration of (7.31 ± 13.43) μg · ml ~ (-1). Conclusion: In the so-called anti-epilepsy “pure Chinese medicine ” preparations dark western medicine is more common, a serious violation of the patient’s right to information, prevent the regular treatment of anti-epilepsy, detrimental to patient health.